ARVO Meeting Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marcus, D.M.
Right arrow Articles by Fine, S.L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Marcus, D.M.
Right arrow Articles by Fine, S.L.
Invest Ophthalmol Vis Sci 2003;44: E-Abstract 3158.
© 2003 ARVO

3158

The Age-Related Macular Degeneration Radiotherapy Trial (AMDRT): 1 Year Results

D.M. Marcus1, E.P. Peskin2, J.A. Alexander2, D. Weissgold3, M.G. Maguire3, A.M. Maguire3 and S.L. Fine3

1 Ophthalmology, Medical College of Georgia, Augusta, GA, United States
2 University of Pennsylvania, Scheie Eye Institute, Philadelphia, PA, United States
3 Section of Ophthalmology, University of Vermont, Burlington, VT, United States

Commercial Relationships: D.M. Marcus, None; E.P. Peskin, None; J.A. Alexander, None; D. Weissgold, None; M.G. Maguire, None; A.M. Maguire, None; S.L. Fine, None.

Grant Identification: Support: NIH, NEI AMD planning grant R21 EY12341

Abstract

Purpose: To determine the efficacy of external beam irradiation for subfoveal choroidal neovascularization (CNV) complicating age-related macular degeneration.
Methods: Ten centers enrolled 89 patients who were randomized to radiotherapy (5 X 4 Gy fractions=20Gy; 6 MeV) versus no radiotherapy (sham treatment or observation). Eligibility criteria included visual acuity greater than or equal to 20/320 and CNV not amenable to MPS laser photocoagulation or photodynamic therapy with verteporfin. Randomization was stratified by lesion type: new CNV (N=80) and recurrent CNV (N=9). The primary outcome measure was change in visual acuity. Secondary outcome measures were fluorescein angiographic lesion size change and incidence of side effects.
Results: At baseline, the radiation and no radiation groups were not different with respect to age (mean 77), gender (58% females), race (99% caucasian), and systemic hypertensive status (57% hypertensive). Baseline visual acuity was not different between the groups (47% greater than or equal to 20/80) at baseline. Fluorescein angiographic features did not differ between the groups (84% minimally classic or occult CNV; 74% comprised of <25% blood; 81% comprised of <25% fibrosis). At 6 months follow-up, 26% of radiated and 50% of eyes not radiated demonstrated loss of greater than or equal to 3 visual acuity lines (p=0.04; stratified {chi}2 test). At 12 months follow-up, 43% of radiated eyes and 50% of eyes not radiated demonstrated loss of greater than or equal to 3 visual acuity lines (p=0.60). No eyes developed radiation retinopathy or optic neuropathy.
Conclusions: External beam irradiation at a dose of 5 X 4 Gy has a very modest and short-lived (6 month) benefit in preserving visual acuity. No obvious safety concerns were observed with this dose. Radiotherapy at similar doses or fraction sizes may be studied as an adjuvant, rather than primary, treatment for subfoveal CNV.

Keywords: age-related macular degeneration • choroid: neovascularization • radiation therapy

© 2003, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. For permission to reproduce any part of this abstract, contact the ARVO Office at arvo{at}arvo.org.




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH